May 2009 Vol 28 No 5

 

Letters/News - CVD prevention saving lives

The National President says - The patient must come first

Canberra commentary - Grave concerns over Schedule 8 drugs

State news

NAPSA update - Constitutional changes for NAPSA to include associate membership

Cover story - Philanthropy and big pharma - closer than you think

Aged care - Silent myocardial ischaemia in the elderly: ‘deathening’ silence

Journal roundup

Old drug new indication Celecoxib - can it prevent pain and cancer?

Early career pharmacist focus - The big five of leadership

Continuing professional development contents

Counselling in practice - I’m having nosebleeds

Supporting pharmacy practice - Disease state management in community pharmacy

Medication review - Adverse events with antipsychotics

The complementary approach - Complementary medicines for cardiovascular disease

Bookzone APF21

Pharmacology revisited - Monoclonal antibodies

Clinical update Drug induced hypertension - a QUM opportunity for Pharmacists?

Conferences/CPE calendar

Evidence base update Statins as primary prevention in patients without dyslipidaemia

CPD Questions  - Answer sheet May 2009 AP (including the March 2009 answers.)

Knowledge in practice

Complementary medicines

Research news - Room for improvement in drug interaction alerts

Product news Botox, Aclasta, PKU Anamix Junior LQ and Lophlex LQ 10, Lexapro, Neupogen and Neulasta, Nexium, Solaris, Intanza, Emerflu.